| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Cryo-Cell International Inc.
$3.71
+0.18 (+5.1%)
D 30Pipeline Score Richly Valued Biotech · Clinical
Market Cap
29.91 M
EPS
-0.33
P/E Ratio
-
Value Trade
21.79 K
-19.41 %
Week
-19.59 %
1 Month
-9.49 %
3 Month
13.87 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
3.25 K
52 Week Range
2.72 - 5
% held by Insiders
47.86 %
% held by Institutions
13.72 %
Enterprise Value
33.58 M
Total Shares
8.07 M
Short %
0.13 %
Float Shares
3.71 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D30
Pipeline Score $3M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 46%
Micro Cap (rank 450 of 832)
Percentile RankCryo-Cell International Inc. faces pipeline headwinds (30/100), with $50M risk-adjusted pipeline value, led by Cord Tissue Mesenchymal Stromal Cells in Autism (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cord Tissue Mesenchymal Stromal Cells Monoclonal antibody Completed | Autism | Phase 2 | NCT04089579 | 33% | $50M | COMPLETED | 137 | - | - | Feb 1, 2024 | - | MEDIUM Jul 25, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in CCEL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
CCEL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-CCEL
May 8, 2026Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL RECEIVES ACCEPTANCE OF COMPLIANCE PLAN FROM NYSE AMERICAN OLDSMAR, FL. –
Cryo-Cell International, Inc. has received approval from NYSE American for its compliance plan to address listing standards. The company was previously notified of a stockholders' deficit and net losses over recent years. With an extended compliance period until September 2027, Cryo-Cell's stock will continue to trade on the NYSE American, pending adherence to the plan. However, there are risks of delisting if compliance isn't achieved by the deadline.
Read more →-CCEL
Mar 12, 2026Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL RECEIVES NYSE AMERICAN CONTINUED LISTING NOTICE OLDSMAR, FL. –
Cryo-Cell International, Inc. has received a continued listing notice from NYSE American due to non-compliance with certain listing standards. The notice cites a stockholders' deficit and net losses in two of the past three fiscal years. Despite this, the company's stock will continue to trade while it formulates a compliance plan. If accepted, the company would have up to 18 months to regain compliance, although uncertainties remain about their ability to do so.
Read more →-CCEL
May 8, 2025Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES CASH DIVIDEND OLDSMAR, FL –
Cryo-Cell International, Inc. has announced a quarterly cash dividend of $0.15 per share, which is a reduction from previous payouts, due to the current economic environment. The dividend will be paid on May 30, 2025, to shareholders recorded by May 21, 2025. The company emphasizes the ongoing evaluation of its dividend policy, indicating it may change in the future. Cryo-Cell remains a pioneer in cord blood banking, complying with industry regulations and striving for quality in its services.
Read more →-CCEL
Oct 30, 2024▲ +25.6%on this news
Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL declares INITIATION OF regular quaRterly CASH DIVIDEND OLDSMAR, FL –
Cryo-Cell International, Inc. announced the initiation of a regular quarterly cash dividend at an initial rate of $0.25 per share for shareholders of record as of November 15, 2024. The payment is expected to occur on November 29, 2024. This decision aims to enhance shareholder value while the Board evaluates the dividend policy based on the company's performance and capital needs. Cryo-Cell, the world's first private cord blood bank, has garnered trust from over 500,000 parents across 87 countries.
Read more →-CCEL
Oct 15, 2024Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2024 FINANCIAL RESULTS OLDSMAR, FL –
Cryo-Cell International, Inc. (CCEL) announced its fiscal third quarter results for 2024, showing a revenue increase to $8.07 million from the previous year's $7.87 million. The company's net income also rose to $1.05 million, up from $681,000 in the same quarter last year. Additionally, Cryo-Cell detailed its ongoing exploration of strategic alternatives and the delay of its Celle Corp. spinoff due to pending arbitration with Duke University. The possibility of introducing quarterly dividends for shareholders was also highlighted in the announcement.
Read more →-CCEL
Mar 25, 2024▲ +7.6%on this news· ran to +25% by day 1
Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL ANNOUNCES PLANS TO EXPLORE STRATEGIC ALTERNATIVES AND SPIN-OFF CELLE CORP. TO MAXIMIZE SHAREHOLDER VALUE OLDSMAR, FL. –
Cryo-Cell International, Inc. announced plans to explore strategic alternatives and is set to spin off its new subsidiary, Celle Corp., to its shareholders. This decision is aimed at maximizing shareholder value through potential equity or debt financings and possible company mergers. The spin-off is anticipated to occur in Cryo-Cell's 2nd or 3rd fiscal quarters and will involve transferring certain assets and liabilities to Celle Corp. Shareholders may receive the spin-off in the form of a stock dividend. Further details will be disclosed in future SEC filings.
Read more →-CCEL
Mar 16, 2022Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE OLDSMAR, FL –
For Immediate Release Contact: Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ANNOUNCES EXTRAVAULT BIOREPOSITORY SERVICE OLDSMAR, FL March 16, 2022 Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company ), the world's first private cord blo
Read more →-CCEL
Feb 22, 2022▲ +7%on this news
Irene Smith 813-749-2102 Ismith@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 OLDSMAR, FL. –
For Immediate Release Contact: Irene Smith Ismith@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2021 OLDSMAR, FL. February 22, 2022 Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the Company ), the world's first pri
Read more →-CCEL
Oct 15, 2021Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021
For Immediate Release Contact: Irene Smith 813-749-2102 Ismith@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL - October 15, 2021 - Cryo-Cell International, Inc. (The Nasdaq Stock Market Symbol: CCEL) (the "Co
Read more →-CCEL
Sep 20, 2021▼ -5.4%on this news
Cryo-Cell International Announces Changes To Its Board of Directors Miami, Fl
Cryo-Cell International Announces Changes To Its Board of Directors Miami, Fl, September 20, 2021 (GLOBENEWSWIRE) -- Cryo-Cell International, Inc. (Nasdaq:CCEL), the leader in cord blood and cord tissue cryopreservation services, announces the appointment of Mr. Mark Portnoy and
Read more →-CCEL
Jul 15, 2021Diane Glanz, Rph, PharmD Investor Relations Consultant 813-749-2195 DGlanz@Cryo-Cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021
For Immediate ReleaseContact: Diane Glanz, Rph, PharmD Investor Relations Consultant DGlanz@Cryo-Cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL - July 15, 2021 - Cryo-Cell International, Inc. (OTC:QB Markets Grou
Read more →-CCEL
Apr 14, 2021David Portnoy Chairman and Co- Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 202
For Immediate ReleaseContact: Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIrst Quarter 2021 FINANCIAL RESULTS OLDSMAR, FL - April 14, 2021 - Cryo-Cell International, Inc. (OT
Read more →-CCEL
Feb 24, 2021David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 OLDSMAR, FL.
For Immediate ReleaseContact: Cryo-Cell International, Inc. dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2020 OLDSMAR, FL. - February 24, 2021 - Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the "Company"),
Read more →-CCEL
Oct 15, 2020David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2020
For Immediate ReleaseContact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD Quarter 2020 FINANCIAL RESULTS OLDSMAR, FL - October 15, 2020 - Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol:
Read more →-CCEL
Jul 10, 2020David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 202
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2020 FINANCIAL RESULTS July 10, 2020 Cryo-Cell Internatio
Read more →-CCEL
Jun 11, 2020David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL
For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ENTERS INTO PATENT OPTION AGREEMENT WITH DUKE UNIVERSITY OLDSMAR, FL June 11, 2020 Cryo-Cell Interna
Read more →-CCEL
May 6, 2020David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2020
CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2020 FINANCIAL RESULTS OLDSMAR, FL April 14, 2020 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company ), the world s first private cord blood bank to separate and store stem cells in 199
Read more →-CCEL
Feb 27, 2020David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2019 OLDSMAR, FL.
For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2019 OLDSMAR, FL. February 27, 2020 Cryo-Cell International, Inc. (OTC:QB Markets Group Sym
Read more →-CCEL
Oct 15, 2019David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2019
For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL THIRD QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL October 15, 2019 Cryo-Cell Internatio
Read more →-CCEL
Jul 15, 2019David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 201
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL SECOND QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL July 15, 2019
Read more →-CCEL
Apr 15, 2019David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2019
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2019 FINANCIAL RESULTS OLDSMAR, FL April 15, 2019 Cryo-Cell
Read more →-CCEL
Feb 28, 2019David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2018 OLDSMAR, FL.
For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2018 OLDSMAR, FL. February 28, 2019 Cryo-Cell International, Inc. (OTC:QB Markets Group S
Read more →-CCEL
Oct 15, 2018David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2018
For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2018 RESULTS OLDSMAR, FL October 15, 2018 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol
Read more →-CCEL
Aug 16, 2018David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com ARTHUR ELLIS AND BRIAN SHEEHY JOIN CRYO-CELL S
ARTHUR ELLIS AND BRIAN SHEEHY JOIN CRYO-CELL S BOARD OF DIRECTORS OLDSMAR, FL August 16, 2018 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company ), the world s first private cord blood bank to separate and store stem cells in 1992, announced that Art
Read more →-CCEL
Jun 15, 2018David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL CONSUMMATES ACQUISITION OF CORD:USE
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL CONSUMMATES ACQUISITION OF CORD:USE ASSETS AND EXTENDS ITS LEADERSHIP POSITION INTO THE PUBLIC CORD BLOOD
Read more →-CCEL
Jun 4, 2018David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL ACQUIRES CORD:USE CORD BLOOD BANK
CORD BLOOD BANKING LEADER CRYO-CELL ACQUIRES CORD:USE CORD BLOOD BANK, INC. OLDSMAR, Fla. June 4, 2018 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company ), the world s first private cord blood bank to separate and store stem cells in 1992, announced
Read more →-CCEL
Apr 16, 2018David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2018
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2018 FINANCIAL RESULTS OLDSMAR, Fla. April 16, 2018
Read more →-CCEL
Feb 28, 2018David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2017 OLDSMAR, FL.
CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL YEAR ENDED NOVEMBER 30, 2017 OLDSMAR, FL. February 28, 2018 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company ), the world s first private cord blood bank to separate and store stem cells in 1992, annou
Read more →-CCEL
Oct 16, 2017David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2017
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2017 RESULTS OLDSMAR, Fla. October 16, 2017 Cryo-Cell International, Inc. (OTC:QB
Read more →-CCEL
Apr 14, 2017David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2017
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2017 FINANCIAL RESULTS OLDSMAR, Fla. April 14, 2017
Read more →-CCEL
Feb 28, 2017David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2016
For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2016 OLDSMAR, Fla. February 28, 2017 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Com
Read more →-CCEL
Apr 14, 2016David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2016
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2016 FINANCIAL RESULTS OLDSMAR, Fla. April 14, 2016
Read more →-CCEL
Mar 2, 2016David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2015
For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2015 OLDSMAR, Fla. March 2, 2016 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (t
Read more →-CCEL
Jul 16, 2015David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL SECOND QUARTER 2015
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL SECOND QUARTER 2015 FINANCIAL RESULTS OLDSMAR, Fla. July 16, 2015 Cryo-Cell Int
Read more →-CCEL
Apr 15, 2015David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2015
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CORD BLOOD BANKING LEADER CRYO-CELL REPORTS FISCAL FIRST QUARTER 2015 FINANCIAL RESULTS OLDSMAR, Fla. April 15, 2015
Read more →-CCEL
Mar 31, 2015Cryo-Cell International, Inc., cord blood banking leader, takes significant ownership stake in Cord Blood America, Inc., and encourages CBAI shareholders to vote against upcoming share authorization proposal TAMPA, FL.
Cryo-Cell International, Inc., cord blood banking leader, takes significant ownership stake in Cord Blood America, Inc., and encourages CBAI shareholders to vote against upcoming share authorization proposal TAMPA, FL. March 31, 2015 Cryo-Cell International, Inc. ( Cryo-Cell )
Read more →-CCEL
Mar 3, 2015David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2014
For Immediate Release Contact: David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2014 OLDSMAR, Fla. March 3, 2015 Cryo-Cell International, Inc. (OTC:QB Markets Group Symbol: CCEL) (the Company )
Read more →-CCEL
Dec 3, 2014Nancy Abramson, Special Projects Marketing Manager Cryo-Cell International, Inc. 813-749-2100 nabramson@cryo-cell.com Cryo-Cell Adopts Three-Year Stockholder Rights Plan Oldsmar, Florida
For Immediate Release Contact: Nancy Abramson, Special Projects Marketing Manager Cryo-Cell International, Inc. 813-749-2100 nabramson@cryo-cell.com Cryo-Cell Adopts Three-Year Stockholder Rights Plan Oldsmar, Florida December 3, 2014 Cryo-Cell International, Inc. (OTC
Read more →-CCEL
Oct 15, 2014David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2014
For Immediate Release Contact: David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FISCAL THIRD QUARTER 2014 RESULTS OLDSMAR, Fla. October 15, 2014 Cryo-Cell International, Inc. (the Company ) (OTC:QB M
Read more →-CCEL
Jul 7, 2014David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS SECOND QUARTER 2014
For Immediate Release Contact: David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS SECOND QUARTER 2014 RESULTS OLDSMAR, Fla. July 7, 2014 Cryo-Cell International, Inc. (OTC:QB Marke
Read more →Older news (43)
- David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FIRST QUARTER 2014Apr 15, 2014
- David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2013Mar 3, 2014
- David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS THIRD QUARTER 2013Oct 15, 2013
- David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS SECOND QUARTER 2013Jul 15, 2013
- David Portnoy Chairman and Co-Chief Executive Officer Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FIRST QUARTER 2013Apr 5, 2013
- David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL REPORTS FINANCIAL RESULTS FOR FISCAL 2012Feb 28, 2013
- David Portnoy, Chairman and Co-CEO Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELLOct 15, 2012
- Key Stakeholders Support Cryo-Cell International Leadership in Proxy Contest OLDSMAR, Fla. (Jul 5, 2012
- Cryo-Cell Leadership Sets the Record Straight on Efforts to Date OLDSMAR, Fla. (Jul 3, 2012
- David Portnoy Cryo-Cell International, Inc. 813-749-2100 dportnoy@cryo-cell.com CRYO-CELL INTERNATIONAL, INC. REPORTS THIRD QUARTER 2011 RESULTS Company Begins the Process of Building a BriOct 18, 2011
- Source: Cryo-Cell International, Inc. On TuesdayAug 30, 2011
- Julia Avery (Investors) Stern Investor Relations, Inc. 212-362-1200 julia@sternir.com Irene Smith (Media) Cryo-Cell International, Inc. 813-749-2100 ismith@cryo-cell.com CRYO-CELL EVALUATES STRATEGIC ALTERNATIVEAug 8, 2011
- Julia Avery (Investors) Stern Investor Relations, Inc. 212-362-1200 julia@sternir.com Irene Smith (Media Inquiries) Cryo-Cell International, Inc. 813-749-2100 ismith@cryo-cell.com CRYO-CELLJul 13, 2011
- Julia Avery (Investors) Stern Investor Relations, Inc. 212-362-1200 julia@sternir.com Irene Smith (Media) Cryo-Cell International, Inc. 813-749-2100 ismith@cryo-cell.com CRYO-CELL INTERNATIJun 21, 2011
- Julia Avery (Investors) Investor Relations 212-362-1200 julia.sternir.com Irene Smith (Media Inquiries) Cryo-Cell International, Inc. 813-749-2100 ismith@cryo-cell.com CRYO-CELL INTERNATIONApr 13, 2011
- Julia Avery (Investors) Stern Investor Relations, Inc. 212-362-1200 julia@sternir.com Irene Smith (Media) Cryo-Cell International, Inc. 813-749-2100 ismith@cryo-cell.com CRYO-CELL REPORTS FFeb 28, 2011
- Lilian Stern (Investors) Investor Relations Stern IR 212-362-1200 lilian@sternir.com Wendi Lee (Media Inquiries) Cryo-Cell International, Inc. 813-749-2100 wlee@cryo-cell.com CRYO-CELL INTEOct 14, 2010
- Lilian Stern (Investors) Investor Relations Stern IR 212-362-1200 lilian@sternir.com Kristin Boza (Media Inquiries) Edelman 312-233-1295 kristin.boza@edelman.com CRYO-CELL INTERNATIONAL, INJul 15, 2010
- Dianne Will (Investors) Investor Relations 518-398-6222 dwill@willstar.net Kristin Boza (Media Inquiries) Edelman 312-233-1295 kristin.boza@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTSApr 13, 2010
- Dianne Will (Investors) Investor Relations 518-398-6222 dwill@willstar.net Kristin Boza (Media Inquiries) Edelman 312-233-1295 kristin.boza@edelman.com CRYO-CELL REPORTS RESULTS FOR FISCALMar 1, 2010
- Dianne Will (Investors) Investor Relations 518-398-6222 dwill@willstar.net Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS TOct 13, 2009
- Dianne Will (Investors) Investor Relations 518-398-6222 dwill@willstar.net Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS SJul 9, 2009
- Gayatri Narayanan (Investors) Edelman 212-704-4577 gayatri.narayanan@edelman.com Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPApr 9, 2009
- Mona J. Walsh (Investors) Edelman 212-704-4598 mona.walsh@edelman.com Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS THIRD QUARTER 2008Oct 15, 2008
- Mona J. Walsh (Investors) Edelman 212-704-4598 mona.walsh@edelman.com Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS FIRSTApr 10, 2008
- CRYO-CELL INTERNATIONAL TO HOLD 2008 ANNUAL MEETING ON JULY 15, 2008 Oldsmar, Fla.Feb 27, 2008
- Mona J. Walsh (Investors) Edelman 212-704-4598 mona.walsh@edelman.com Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTFeb 11, 2008
- SPECIAL STOCKHOLDERS MEETING TO ELECT DIRECTORS SET FOR MARCH 4, 2008 Oldsmar, Fla.Jan 22, 2008
- DELAWARE CHANCERY COURT REJECTS PORTNOY REQUEST TO SEAT DISSIDENT SLATE IN CRYO-CELL ELECTION; INCUMBENT BOARD TO CONTINUE IN OFFICE UNTIL SPECIAL STOCKHOLDERS MEETING Oldsmar, Fla.Jan 17, 2008
- Mona J. Walsh (Investors) Edelman 212-704-4598 mona.walsh@edelman.com Kellie Hotz (Media Inquiries) Edelman 312-240-2701 kellie.hotz@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS THIRDOct 15, 2007
- Katie Wood Edelman 312-240-2827 katie.wood@edelman.com CRYO-CELL INTERNATIONAL, INC. REPORTS FIRST QUARTER 2007 RESULTS Cryo-Cell Provides Update on Plureon Stem Cell Service and on the ComApr 16, 2007
- Denise Roche The Ruth Group, Inc. 646 536 7008 Droche@theruthgroup.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTS FOR FISCAL 2006 Oldsmar, FLFeb 28, 2007
- Denise Roche The Ruth Group, Inc. 646 536 7008 droche@theruthgroup.com CRYO-CELL INTERNATIONAL REPORTS THIRD QUARTER 2006 RESULTS Company Leverages Strong Balance Sheet to Grow Market ShareOct 16, 2006
- Denise Roche The Ruth Group, Inc. 646 536 7008 droche@theruthgroup.com CRYO-CELL INTERNATIONAL REPORTS SECOND QUARTER 2006 RESULTS Company Leverages Strong Balance Sheet to Launch New ServiJul 17, 2006
- Denise Roche The Ruth Group, Inc. 646 536 7008 droche@theruthgroup.com CRYO-CELL INTERNATIONAL REPORTS FIRST QUARTER 2006 RESULTS Company Plans to Leverage Strong Balance Sheet to Launch NeApr 11, 2006
- Francesca DeMartino The Ruth Group, Inc. 646 536 7024 Fdemartino@theruthgroup.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTS FOR FISCAL 2005 Company Reports Eighth Consecutive Quarter ofFeb 27, 2006
- Francesca DeMartino The Ruth Group, Inc. 646 536 7024 Fdemartino@theruthgroup.com CRYO-CELL INTERNATIONAL ANNOUNCES ACCELERATED VESTING OF STOCK OPTIONS WITH EXERCISE PRICES IOct 11, 2005
- Francesca DeMartino The Ruth Group, Inc. 646 536 7024 Fdemartino@theruthgroup.com CRYO-CELL INTERNATIONAL REPORTS THIRD QUARTER 2005 RESULTS Company Reports Increased Revenues and Strong CaOct 4, 2005
- CRYO-CELL Board Appoints Mercedes Walton Chief Executive Officer Wednesday August 17 Appointment Reflects Walton s Strategic Leadership as Interim CEO OLDSMAR, Fla., Aug. 17 /PRNewswire-FirstCall/ The BoardAug 19, 2005
- Francesca DeMartino The Ruth Group, Inc. 646 536 7024 Fdemartino@theruthgroup.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTS FOR SECOND QUARTER 2005 Company Reports Net Income, IncreasedJul 15, 2005
- Todd Atenhan 813-749-2100 813-855-4745 (Fax) investor.relations@cryo-cell.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTS FOR FIRST QUARTER 2005 Company Reports Net Income, Increased ReveApr 5, 2005
- Todd Atenhan 813-749-2100 813-855-4745 (Fax) investor.relations@CRYO-CELL.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTS FOR FISCAL 2004 Company Reports Net Income, Increased Revenues, HFeb 11, 2005
- Todd Atenhan 727-450-8000 727-723-0444 (Fax) investor.relations@CRYO-CELL.com CRYO-CELL INTERNATIONAL, INC. REPORTS RESULTS FOR THIRD QUARTER 2004 Company Reports Net Income, Increased ReveOct 4, 2004
Competitive Position
How CCEL ranks across every disease it competes inCompetitive Position is a premium feature
See how CCEL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial